Roche's Phesgo (fixed-dose combination of Perjeta and Herceptin) Receives the US FDA's Approval for Early and Metastatic HER2-Positive Breast Cancer
Shots:
- The approval is based on P-III FeDeriCa study which involves assessing of Phesgo (SC) + CT vs Perjeta (pertuzumab- IV) & Herceptin (trastuzumab- IV) + CT in 500 patients with HER2+ve early breast cancer treated in the neoadjuvant (before surgery) and adjuvant (after surgery) settings evaluated PK- efficacy- and safety
- The study met its 1EPs showing non-inferior levels of Phesgo (SC) vs Perjeta (IV) in the blood plus no cardiac toxicity was demonstrated also the safety profile was comparable including no new safety signals. Additionally- in the P-II PHranceSCa study- 85% (136/160) patients preferred SC vs IV administration involving less time in the clinic with more comfort
- Phesgo is an (FD- SC) formulation which involves a combination of pertuzumab + trastuzumab developed using Halozyme Therapeutics’ Enhanze drug delivery technology and administered within 8 mins for initial dosing and 5 mins for maintenance dosing
Click here to read full press release/ article
Ref: Roche | Image: Roche
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com